SU-E-J-06: Additional Imaging Guidance Dose to Patient Organs Resulting From X-Ray Tubes Used in CyberKnife Image Guidance System

2015 ◽  
Vol 42 (6) ◽  
pp. 3264-3264 ◽  
Author(s):  
A Sullivan ◽  
G Ding
2010 ◽  
Vol 55 (23) ◽  
pp. 7345-7362 ◽  
Author(s):  
K H Song ◽  
R Pidikiti ◽  
S Stojadinovic ◽  
M Speiser ◽  
S Seliounine ◽  
...  

2019 ◽  
Vol 46 (3) ◽  
pp. 1355-1370 ◽  
Author(s):  
Bin Cai ◽  
Eric Laugeman ◽  
Thomas R. Mazur ◽  
Justin C. Park ◽  
Lauren E. Henke ◽  
...  

2008 ◽  
Vol 35 (8) ◽  
pp. 3809-3819 ◽  
Author(s):  
Justin P. Vinci ◽  
Kenneth R. Hogstrom ◽  
Daniel W. Neck
Keyword(s):  

2007 ◽  
Author(s):  
Luis F. Gutiérrez ◽  
Guy Shechter ◽  
Douglas Stanton ◽  
Sandeep Dalal ◽  
Daniel Elgort ◽  
...  

2011 ◽  
Author(s):  
Sungwon Yoon ◽  
Brian P. Wilfley ◽  
Keith Jasperson ◽  
Ganesh Krishna ◽  
Rebecca Fahrig

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A422-A422
Author(s):  
Ravi Murthy ◽  
Rahul Sheth ◽  
Alda Tam ◽  
Sanjay Gupta ◽  
Vivek Subbiah ◽  
...  

BackgroundImage guided intra-tumor administration of investigational immunotherapeutic agents represents an expanding field of interest. We present a retrospective review of the safety, feasibility & technical nuances of real-time image guidance for injection & biopsy across a spectrum of extracranial solid malignancies utilizing the discipline of Interventional Radiology.MethodsPatients who were enrolled in image guided intratumoral immunotherapy injection (ITITI) clinical trials over a 6 year period (2013–19) at a single tertiary care cancer center were included in this analysis. Malignancy, location, imaging guidance utilized for ITITI & biopsy for injected (adscopal) & non-injected (abscopal) lesions were determined and categorized. Peri-procedural adverse events were noted.Results262 pts (146 female, 61 yrs median) participating in 29 immunotherapeutic clinical trials (TLR & STING agonists, gene therapy, anti CD-40, viral/bacterial/metabolic oncolytics) met study criteria. Malignancies included melanoma 88, sarcoma 32, colorectal 29, breast 23, lung 17, head & neck 15, ovarian 8, neuroendocrine 7, pancreatic adenocarcinoma 6, 3 each (cholangioCA, endometrial, bladder, GI tract), 2 each (RCC, thymicCA, lymphoma, merkel cell, prostate) & others 1 each (CUP, GIST, dermatofibrosarcoma, DSRT, neuroblastoma, thyroid). All 169 & 93 patients received the intended 1371 ITITI in parietal (abdominal/chest wall, extremity, neck, pelvis) or visceral (liver, lung, peritoneum, adrenal) locations respectively; 83 patients received lymph node injections within either location. Imaging guidance was US in 68% of the cohort (US 161, CT+US 19); CT was used in 30% (81) & MRI in 1 patient. Median diameter of the ITITI lesion was 32 mm (8–230 mm). Median volume of the ITITI therapeutic material/session was 2 ml (1–6.9 ml). Lesions were accessed using a coaxial technique. ITITI delivery needles used at operator preference & tailored to lesion characteristics were either a 21G/22G Chiba, 21G Profusion (Cook Medical), 22G Morrison (AprioMed), 25G hypodermic (BD) & 18G Quadrafuse (Rex Medical). 2840 core biopsies (>18G Tru-cut core, Mission, Bard Medical) were performed in 237 patients during 690 procedures; biopsy sessions were often concurrent & of the ITITI site. 137 patients also underwent biopsy of a non-ITITI site (89 parietal location). Dimensions of the non-ITITI lesion were median 10 mm (7–113 mm); US image guidance was used in 97 patients (72%) to obtain a total of 1257, >18G Tru-core samples. 1.3% of injections resulted in SAE (NCI CTC AE >3) and 0.5% of 4097 biopsies developed major complications (SIR Criteria); both categories were manageable.ConclusionsUtilizing real time image guidance, ITITI to the administration of a myriad of investigational immunotherapeutic agents with concomitant biopsy procedures to date are associated with a high technical success rate & favorable safety profile.AcknowledgementsJoshua Hein, Mara Castaneda, Jyotsna Pera, Yunfang Jiang,Shuang Liu, Holly Liu and Anna LuiTrial RegistrationN/AEthics ApprovalThe study was approved by Institution’s Ethics Board, approval number 2020-0536: A retrospective study to determine the safety, feasibility and technical challenges of real-time image guidance for intra-tumor injection and biopsy across multiple solid tumors.Consent2020-0536 Waiver of Informed ConsentReferenceSheth RA, Murthy R, Hong DS, et al. Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer. JAMA Netw Open 2020;3(7):e207911. doi:10.1001/jamanetworkopen.2020.7911


2014 ◽  
Vol 1044-1045 ◽  
pp. 1343-1348
Author(s):  
Wu Can He ◽  
Shou Yi Liao ◽  
Zuo Yu Zhang ◽  
He Xin Zhang

Dynamic IR image generation of space target is one of the key technologies in hardware in the loop simulation for the infrared imaging guidance system. The three-dimensional entity model is created in the Creator, Sinda/Fluint is used to analyze each part of dynamic infrared radiation characteristics from on-orbit Space Target, on the basis of the LRS infrared star catalogues, celestial background modeling is built. In Vega, the dynamic IR image of space target is generated. The simulation results show that the dynamic IR image of Space Target provide the important objective basis for the hardware in the loop simulation for the infrared imaging guidance system.


Sign in / Sign up

Export Citation Format

Share Document